Department of Oncology, People's Hospital of Xintai City, No. 1329 Xinfu Road, Xintai, 271200 Shandong Province China.
Cell Mol Biol Lett. 2019 Feb 5;24:4. doi: 10.1186/s11658-018-0129-6. eCollection 2019.
We investigated the potential regulatory role of miR-219-5p in esophageal squamous cell carcinoma (ESCC) and looked at the underlying mechanisms in ESCC.
Real-time PCR was used to determine the levels of miR-219-5p in ESCC tissues and cell lines. The effects of miR-219-5p and cyclin A2 (CCNA2) on cell proliferation and cell cycle progression were evaluated using MTT, colony formation and flow cytometry assays with ESCC cell lines EC9706 and TE-9. Bioinformatics techniques and the luciferase reporter assay were applied to validate CCNA2 as the miR-219-5p target in ESCC cells. The mRNA and protein levels of CCNA2 were measured using real-time PCR and western blotting.
MiR-219-5p expression was significantly lower in ESCC tissues and cells than in healthy tissues. Upregulation of miR-219-5p repressed cell proliferation and induced cell cycle arrest at the G2/M phase. CCNA2 was identified and confirmed as a direct downstream target of miR-219-5p and its expression negatively correlated with miR-219-5p profiles in ESCC tissues. Knockdown of CCNA2 potentiated the effects of miR-219-5p on cell proliferation and cell cycle distribution.
Our results demonstrate that miR-219-5p might function as a tumor suppressor by directly targeting CCNA2 expression. It could serve as a new therapeutic target for ESCC.
我们研究了 miR-219-5p 在食管鳞状细胞癌(ESCC)中的潜在调控作用,并探讨了其在 ESCC 中的潜在机制。
实时 PCR 用于确定 ESCC 组织和细胞系中 miR-219-5p 的水平。使用 MTT、集落形成和流式细胞术检测 miR-219-5p 和细胞周期蛋白 A2(CCNA2)对 ESCC 细胞系 EC9706 和 TE-9 增殖和细胞周期进程的影响。生物信息学技术和荧光素酶报告基因检测用于验证 CCNA2 是 ESCC 细胞中 miR-219-5p 的靶基因。使用实时 PCR 和 Western blot 检测 CCNA2 的 mRNA 和蛋白水平。
miR-219-5p 在 ESCC 组织和细胞中的表达明显低于健康组织。上调 miR-219-5p 抑制细胞增殖并诱导细胞周期停滞在 G2/M 期。鉴定并证实 CCNA2 是 miR-219-5p 的直接下游靶基因,其表达与 ESCC 组织中 miR-219-5p 的表达谱呈负相关。下调 CCNA2 增强了 miR-219-5p 对细胞增殖和细胞周期分布的影响。
我们的结果表明,miR-219-5p 可能通过直接靶向 CCNA2 表达发挥肿瘤抑制作用。它可能成为 ESCC 的新治疗靶点。